ABOUT US

At Dreavent, our mission is to improve human health by advancing promising new therapies in important diseases currently lacking effective treatments

We are dedicated to making a meaningful impact on patients' lives through our innovative approach and strategic focus.

OUR STRATEGIC FOCUS

Breakthrough Therapeutics

We prioritize the development of innovative and differentiated therapeutic mechanisms with the potential to revolutionize patient care. Our focus spans critical areas such as Oncology, Neurology, Immunology and Inflammation, Cardiovascular, and Metabolic diseases. By targeting these areas, we aim to bring about significant improvements in health outcomes.

Rigorous Project Selection

We employ a rigorous selection process to identify the most promising investment opportunities. Our team of experts meticulously evaluates thousands of potential projects to select only a few that meet our high standards. This careful vetting process ensures that we focus our resources on the most impactful and viable therapeutic developments.

Minimizing Risks

Our current fund, Engine 2024, opening H2 of 2024, is designed to mitigate various risks, including those related to science, technology, safety, financing, and commercial viability. We achieve this by selecting advanced stage companies that are supported by robust venture capital and major pharmaceutical partners. This strategy ensures that our investments are not only promising but also well-supported.

Ecosystem Collaboration

Since 2011, our Managing Partner Wendy Nelson has been instrumental in fostering biotech connectivity through her Boston Biotech Forums. At Dreavent, we leverage this extensive network to enhance collaboration with investors, increase deal flow, and drive innovation. Our commitment to ecosystem collaboration helps us stay at the forefront of biotech advancements.

OUR COMMITMENT

We Support the Development of Future Cures

Dreavent is committed to advancing the frontiers of medical science. By investing in promising new therapies, we strive to address unmet medical needs and improve the quality of life for patients worldwide. Our strategic focus, rigorous selection process, and collaborative efforts underpin our mission to make a lasting impact on human health.

Our investment strategy is centered on supporting the development of future cures, with a dual focus on advancing health innovations that benefit both people and the planet. We prioritize minimizing risks by employing a carefully crafted approach to our investment decisions. This involves partnering with large funds to mitigate financial uncertainties and aligning with major pharmaceutical companies to invest in technologies with proven potential.

In our pursuit of safety and reliability, we commit to investing in companies whose products have already been successfully tested on animals and are in production using established methods. Our investment strategy is further defined by collaborating exclusively with those pharmaceutical companies and funds that have demonstrated a track record of positive outcomes, ensuring that we partake in ventures that are not only promising but also grounded in a history of success.

Dreavent Engine 2024

Opening H2 2024

Request more info

Previous Investments

7 Companies

See Portfolio

Voices of success

  • Robert T. Connelly - CEO - Elicio Therapeutics

    “Dreavent led our Series C, financing Elicio in a historically difficult biotech financing era, working with us for a full year-plus relentlessly, over several closes.

    Since the Series C closed in 2022 Dreavent has been incredibly supportive and resourceful, making connections with other investors and potential business development partners.

    They are incredibly responsive, creative, with great sense of urgency, and worldwide networks. I've been a CEO for 24 years and I have never worked with an investor who was so invested in the success of my company, with a "whatever it takes" mentality. It feels very much like they are on the team, not just an investor- true believers. They are also just good people which makes working through the tough issues SO much easier. I could not recommend anyone more highly."

  • Tara Nickerson - CEO - Therini Bio

    "Therini Bio is thrilled to have Dreavent join our Series A financing. After taking time to thoughtfully get to know the management team and our plans, Dreavent fully committed to Therini's long-term vision for developing fibrin-targeting therapeutics intended to halt neuroinflammation in diseases including neurodegenerative and retinal diseases.

    The diligence process was efficient, with clear communication and high degree of transparency from the Dreavent team. They are also understanding about changes that inevitably arise in an early stage company like ours. Gorka has already become a strong supporter and trusted partner to Therini, making helpful introductions for the company through his broad investor network.

    We appreciate Dreavent's investment and continued support!"

  • David Darst - COO/CFO - Inspirna

    "Dreavent has been a very supportive investor in Inspirna since 2022. Their diligence process was straightforward and efficient, and they are transparent throughout. Dreavent's long term focus was helpful as Inspirna seeks to tackle difficult problems in cancer metastasis and progression.

    Our company is pleased to count Dreavent as an institutional investor and we look forward to continuing to work with Gorka Fius and Bill Korinek as Inspirna seeks to bring new first-in-class cancer medicines to patients."

  • Kevin Heyeck - CEO - Chimeron Bio

    "Having raised a venture capital fund and invested in early stage life science companies as a venture capitalist and now leading an innovative, next- generation mRNA company, as CEO, I recognize how important having a committed, talented venture team like Dreavent is to the success of companies like Chimeron Bio.

    Capital is an essential ingredient, but multifold more impactful when underpinned by the vision, expertise and non- financial resources that Dreavent brings with its investment."

  • Tien Lee, M.D. - CEO - Aardvark Therapeutics

    "As CEO of Aardvark Therapeutics, Inc., I would like to convey gratitude and appreciation for the support and steady conviction of Dreavent. Since their investment into Aardvark's Series B, it was clear that the Dreavent team was driven by a rational long- term approach vs only a quick incremental win.

    Importantly, Dreavent has been continually supportive in ways beyond their investment, leveraging their extensive network and making strategic introductions whenever the opportunity arose. It has been a pleasure and a positive experience working with Dreavent.

    Moreover, recognizing the significant contributions Dreavent has made to our company's growth and success, we were thrilled to have them participate in our Series C round which was substantially oversubscribed.""

  • Samara Rahman - Elicio Therapeutics Pancreatic Cancer Patient

    "I'm doing everything that I did before my diagnosis can do anything that want. I can walk long distances; I can swim and I can ride my bike again"

  • Bill Korinek - CEO - Astrocyte Pharmaceuticals

    "Working with this team has proven their reliability in decision-making. They consistently demonstrate thorough analysis and a deep understanding of the investment landscape, which has significantly contributed to our success. Their expertise and solid judgment have made them invaluable partners."